Allysta Pharmaceuticals Developing Multi-Kinase Inhibitor To Treat Glaucoma

Aly1337 is a novel, small-molecule multi-kinase inhibitor that Allysta Pharmaceuticals Inc. is developing to treat glaucoma, said Henry Hsu, MD, Founder and CEO. Kinase, particularly Roh kinase, plays a key role in preventing aqueous outflow through the trabecular meshwork, thus contributing to increasing intraocular pressure. Among the kinases Aly1337 targets is kinase LRRK2, which, according to Dr. Hsu, has not been previously described as active in glaucoma.


Allysta Pharmaceuticals

Henry Hsu, MD

Henry Hsu, MD is the Founder and CEO of Allysta Pharmaceuticals. He has been engaged in ophthalmic drug development for over 10 years.

View Full Profile